**Core tip:** Patients with acute, recurrent acute and chronic pancreatitis were classified as per M-ANNHEIM stages, separately based on the results of two exocrine function tests (acid steatocrit method and faecal elastase test) for comparison. A statistically significant difference was seen between the M-ANNHEIM stages as classified separately by the two tests. Faecal elastase-1 estimation performed better than the acid steatocrit test for use in the staging of pancreatitis by the M-ANNHEIM classification since it diagnosed a higher proportion of patients with exocrine dysfunction.

INTRODUCTION
============

Steatorrhoea from pancreatic insufficiency increases in frequency as chronic pancreatitis (CP) advances and forms an important parameter for staging the disease in various classification systems\[[@B1]-[@B3]\]. The M-ANNHEIM classification, a new system for staging and assessing the severity of pancreatitis, subdivides the disease into 5 stages based on pain and pancreatic functions\[[@B1]\]. Different pancreatic function tests (PFT) and tests for assessing steatorrhoea have been in use for assessing exocrine pancreatic function (EPF) in patients with CP\[[@B4]\]. PFT have also been used for diagnosing CP when imaging studies are inconclusive for the same as happens in early stages of the disease\[[@B4]\]. Direct PFT like the secretin test have a greater sensitivity and help in diagnosing CP in its moderate to late stages as compared to early stages of the disease\[[@B4]\]. However, the test is cumbersome, not easily available, poorly standardised across centres, poses difficulty in measuring the enzyme output and is poorly tolerated by some patients due to the need for oro-duodenal intubation\[[@B5]\]. The 72-h quantitative faecal fat estimation is considered the best method for assessing steatorrhoea. A major drawback of this method has been the need to collect stool specimen for 72 h and to store and process them\[[@B6]\].

The acid steatocrit method correlates well with the 72-h quantitative faecal fat estimation and has a sensitivity, specificity and positive predictive value of 100%, 95% and 90% respectively, and acts as an easier alternative\[[@B7],[@B8]\]. The other advantages of this method are its simplicity, reliability and cost-effectiveness for evaluating steatorrhoea in CP\[[@B8]-[@B11]\].

Faecal elastase-1 (FE-1), is a useful indirect pancreatic function test in which a random spot stool sample can be used to identify exocrine pancreatic insufficiency (EPI) in well established CP, the situation in which steatorrhoea commonly occurs\[[@B12]-[@B14]\]. Studies indicate that FE-1 is useful in estimating fat malabsorption in CP and correlates well with the acid steatocrit method\[[@B15]\].

Not many studies have compared FE-1 and the acid steatocrit method for evaluating EPF in CP. The aim of our study was to determine the usefulness of stool fat analysis by the acid steatocrit method and FE-1 estimation in the staging of pancreatitis using the M-ANNHEIM classification system.

MATERIALS AND METHODS
=====================

Patients
--------

Consecutive patients with pancreatitis presenting to the Department of Gastroenterology and Hepatology, Kasturba Hospital, Manipal between June 2009 and June 2013 were prospectively enrolled in this cross sectional study. Patients underwent detailed clinical evaluation and were classified to have AP, RAP and CP. AP was defined as a single episode of any two of typical upper abdominal pain, raised serum amylase and/or lipase three times above the upper limit of normal and evidence of pancreatitis on imaging\[[@B16]\]. Patients presenting with more than one episode of acute pancreatitis with complete resolution of symptoms in between the episodes and no evidence of CP on imaging were considered to have RAP\[[@B17],[@B18]\]. CP was defined by the presence of pancreatic calcifications and/or ductal changes, visualized by ultrasonography, computed tomography (CT), endoscopic ultrasound (EUS) ("consistent with" and "suggestive of" CP by the Rosemont criteria), endoscopic retrograde cholangiopancreatography or magnetic resonance cholangiopancreatography (MRCP)\[[@B19],[@B20]\].

Stool samples were collected from all patients in two separate containers and one sample was stored at -80 °C, for estimation of FE-1 by ELISA by using a monoclonal antibody based ELISA kit (ScheBo Biotech, Giessen, Germany) as per manufacturer's instructions. Values of ≥ 200 μg per gram of stool, 100 and 200 μg per gram and \< 100 μg per gram were categorised as normal, mild to moderate EPI and severe insufficiency respectively\[[@B21]\].

Stool fat estimation by the acid steatocrit method
--------------------------------------------------

Semiquantitative stool fat estimation by the acid steatocrit method was done on random spot stool samples as proposed by Tran et al\[[@B11]\]. 500 mg of stool was diluted with water and homogenized for 2 to 5 min. 500-μL aliquot of the homogenized stool were added with 100 mL of Perchloric acid and the pH was confirmed to be \< 1. The mixture was aspirated into a capillary tube, sealed at one end and centrifuged at 13000 revolutions per minute for exactly 15 min\[[@B9],[@B11]\]. The length of the fatty layer and the length of the solid layer were measured. Acid steatocrit (%) was obtained by the formula: fatty layer/(fatty layer + solid layer) × 100. The stool fat (in grams/day) was calculated by the equation: -0.43 + (0.45 × acid steatocrit %)\[[@B9]\]. Steatorrhoea was diagnosed when the stool fat excretion was 7 g/d or higher\[[@B4]\].

Patients were classified as per the M-ANNHEIM staging system first using the acid steatocrit method and then by using the FE-1 test also for comparison.

Statistical analysis
--------------------

Independent Student's *t*-test and the χ^2^ test were used as appropriate. Spearman's rho was used to analyse the correlation between the results of the two tests for exocrine function. The Kruskal-Wallis test was used to compare non normal continuous variables between the various M-ANNHEIM stages. A *P* value of \< 0.05 was considered as statistically significant. The Mann-Whitney *U* test was used to compare continuous variables between any two M-ANNHEIM stages with Boneferonni adjustments for multiple pairwise comparisons considering a *P* value of \< 0.008 as statistically significant for 6-pairwise comparison. The McNemar's test was used to compare the nominal data. A *P* value of \< 0.05 was considered as statistically significant. The statistical review for this study was performed by a biomedical statistician.

The study protocol was approved by the Ethics Committee of Manipal University. All study participants or their legal guardians provided written informed consent prior to study enrolment.

RESULTS
=======

Of the 194 consecutive patients recruited, 13 (6.8%) had AP, 65 (33.5%) had RAP and 116 (59.7%) had CP. Their baseline characteristics are shown in Table [1](#T1){ref-type="table"}.

###### 

Demographic and clinical features of patients identified with pancreatitis based on imaging criteria

                                                                      **AP (*n* = 13)**   **RAP (*n* = 65)**   **CP (*n* = 116)**   ***P* value**
  ------------------------------------------------------------------- ------------------- -------------------- -------------------- ---------------
  Age (yr) (mean ± SD)                                                29.8 ± 11.6         29.0 ± 11.5          33.3 ± 14.2          0.10
  Male: female                                                        12 : 1              57 : 8               96 : 20              0.53
  Alcoholic pancreatitis                                              2 (15.4)            19 (29.2)            28 (24.1)            0.10
  (≥ 50 g/d)                                                                                                                        
  Idiopathic pancreatitis                                             11 (84.6)           46 (70.8)            88 (75.9)            0.52
  Duration of symptoms (in months) \[median (interquartile range)\]   0 (0-0.2)           7.0 (3.5-24.0)       24.0 (4.0-48.0)      \< 0.001
  VAS (mean ± SD)                                                     5.4 ± 2.0           6.4 ± 2.31           5.4 ± 2.5            0.02

A *P* value of \< 0.05 was considered statistically significant.

Correlation between exocrine insufficiency assessed by acid steatocrit and FE-1 estimation
------------------------------------------------------------------------------------------

EPI was tested by acid steatocrit and FE-1 by ELISA in all 194 patients. Stool fat analysis by acid steatocrit method showed a significant negative correlation (Spearman's rho = -0.376, *P* \< 0.001) with FE-1 indicating that both methods had a good agreement for assessing EPI. None of the patients with AP or RAP showed evidence of EPI by either test. Among a total of 116 patients with CP, 61 (52.5%) and 79 (68.1%) patients showed the presence of EPI by the acid steatocrit method and FE-1 respectively. This difference was statistically significant (χ^2^ test, *P* \< 0.001).

M-ANNHEIM staging using the acid steatocrit test
------------------------------------------------

Since all patients in the present study consulted for abdominal pain, there were no patients with stage IV disease as per the M-ANNHEIM classification. The median (IQR) stool fat excretion levels as assessed by the acid steatocrit method were significantly different between the M-ANNHEIM stages 0, I, II and III in a 6-pairwise comparison (*P* \< 0.001, by Kruskal-Wallis test; Table [2](#T2){ref-type="table"}). The stool fat excretion was also significantly different when compared between any two stages except between stages 0 and I (Table [2](#T2){ref-type="table"}).

###### 

Stool fat in grams/day by acid steatocrit in M-ANNHEIM stages of pancreatitis

  **M-ANNHEIM stage (*n* %)**   **Median (IQ range) of stool fat in g/d**
  ----------------------------- -------------------------------------------
  0, 13 (6.7)                   6.3 (6.0-6.6)
  I, 87 (44.8)                  6.3 (5.9-6.4)
  II, 89 (45.8)                 7.5 (6.4-10.8)
  III, 5 (2.5)                  15.3 (12.0-15.6)

A statistically significant difference was present between the different M-ANNHEIM stages (*P* \< 0.001, Kruskal-Wallis test). Comparison between any two stages showed a statistically significant difference between stages 0 and II, and stages II and III (*P* = 0.002, Mann-Whitney *U* test) and also between stages 0 and III, I and II, I and III (*P* \< 0.001; Mann-Whitney *U* test). A *P* value of \< 0.008 was considered statistically significant for such comparisons between any two groups after Alpha adjustment.

M-ANNHEIM staging using FE-1 estimation
---------------------------------------

The median (IQR) FE-1 values were significantly different between the different M-ANNHEIM stages in a 6-pairwise comparison (*P* \< 0.001, by Kruskal-Wallis test, Table [3](#T3){ref-type="table"}). These values were also significantly different when compared between any two stages except between stages 0 and I (Table [3](#T3){ref-type="table"}).

###### 

Faecal elastase-1 levels in M-ANNHEIM stages of pancreatitis

  **M-ANNHEIM stage (*n* %)**   **Median (IQ range) of stool fat in g/d**
  ----------------------------- -------------------------------------------
  0, 13 (6.7)                   289.0 (249.0-383.2)
  I, 85 (43.8)                  389.1 (263.2-436.1)
  II, 75 (38.6)                 144.3 (108.9-219.0)
  III, 21 (10.8)                87.6 (41.1-119.1)

A statistically significant difference was present between the different M-ANNHEIM stages (*P* \< 0.001, Kruskal-Wallis test). Comparison between stages 0 and II, 0 and III, I and II, and II and III showed a statistically significant difference (*P* \< 0.001 for all comparisons, Mann-Whitney *U* test). A *P* value of \< 0.008 was considered statistically significant for such comparisons between any two groups after Alpha adjustment.

Tests for exocrine function - relevance to M-ANNHEIM staging
------------------------------------------------------------

To determine the usefulness of the two methods of assessing EPI for use in the M-ANNHEIM staging, we compared the number of patients in M-ANNHEIM stages obtained separately by using acid steatocrit and FE-1 estimations. As shown in Table [4](#T4){ref-type="table"}, 28 (14.4%) patients had a change in stage by using FE-1 as against the use of acid steatocrit. 7 (3.6%), 5 (2.5%), 16 (8.2%) shifted from stage I to II, II to I and II to III respectively. This difference was statistically significant (*P* \< 0.001, Mc Nemar's test; Table [4](#T4){ref-type="table"}).

###### 

Comparing the number of patients based on M-ANNHEIM staging by acid steatocrit and faecal elastase-1 estimations *n* (%)

  **M-ANNHEIM stages**   **Acid steatocrit method**   **FE-1 test**
  ---------------------- ---------------------------- ---------------
  0                      13 (06.7)                    13 (06.7)
  I                      87 (44.8)                    85 (43.8)
  II                     89 (45.8)                    75 (38.6)
  III                    05 (2.5)                     21 (10.8)

A *P* value \< 0.05 was considered statistically significant. A statistically significant difference was present between the number of those assessed by both methods in M-ANNHEIM stages (*P* \< 0.001, Mc Nemar's test). FE-1: Faecal elastase-1.

DISCUSSION
==========

By comparing M-ANNHEIM stages of pancreatitis as determined by using the acid steatocrit method and FE-1 levels we have shown that 14.4% of patients had a change in stage, most often a move to a higher stage, with the use of the latter. This is because FE-1 estimation confirmed EPI in a significantly higher number of patients compared to the acid steatocrit method. Though the tests used in our study measure different aspects of EPI *i.e*., enzyme secretion and fat excretion respectively, the results of the two showed a high degree of correlation as expected. The lower rate of detection of EPI by the acid steatocrit test could possibly be attributed to the disadvantages this method. These include a lack of standardisation of the test and the effect of dietary fat intake at the time of sample collection on the test results\[[@B15],[@B22]\]. The number of patients in M-ANNHEIM stages 0 and III were smaller and a higher number would have enhanced the quality of this study.

Unlike with the acid steatocrit method FE-1 estimation offers many advantages. In addition to its high sensitivity for assessing moderate to severe EPI, it correlates well with the findings of imaging studies in patients with CP and unlike other pancreatic enzymes such as chymotrypsin, elastase is not degraded as it passes through the gut\[[@B6],[@B15],[@B23]-[@B26]\]. Bian et al\[[@B27]\] have shown that the secretin-enhanced MRCP (sMRCP) significantly correlates with the FE-1 test to quantify the pancreatic exocrine function in patients with CP based on the M-ANNHEIM staging. However, sMRCP has its own limitations in the detection of EPI in patients with CP, given its high cost, the semiquantitaive nature of its results and a modest sensitivity of 69%\[[@B28]\]. The limitations of FE-1 estimation such as its lower sensitivity for detecting mild EPI should however be kept in mind while using this test\[[@B4],[@B6]\].

Estimation of 72-h stool fat excretion and the secretin test are considered the gold standard for assessing steatorrhoea and EPI respectively. It is likely that these tests would have provided different results if we had used them in the M-ANNHEIM staging of pancreatitis. A recent study showed that FE-1 is highly sensitive to diagnose EPI, but low on specificity as compared to the 72-h stool fat excretion test\[[@B29]\]. However, 72-h stool fat excretion and the secretin test are demanding on patients and laboratories alike and are hence uncommonly used at present\[[@B6]\]. It is unlikely that a simple test for steatorrhoea like the spot faecal fat test using Sudan staining would have performed any better than FE-1 estimation but this needs to be evaluated in future studies.

Accurate staging of pancreatitis is important to study the natural history of the disease and the effect of interventions on the same. It will also help in comparing the results of different studies. It is possible that the additional use of biomarkers will improve the staging systems and this needs to be explored in future studies. An earlier report from our centre showed that serum MCP-1 levels were lower in patients with CP and EPI as compared to those diagnosed with CP but without EPI\[[@B30]\]. Future studies combining tests for pancreatic function and biomarkers may help in the early detection of CP.

While the assessment of EPF by acid steatocrit and FE-1 correlated well with each other the latter detected EPI in a significantly higher number, thereby placing a larger number of patients in higher stages of disease as per the M-ANNHEIM classification. We recommend that the FE-1 test should be used for staging pancreatitis by the M-ANNHEIM classification.

COMMENTS
========

Background
----------

Exocrine pancreatic insufficiency (EPI) increases as chronic pancreatitis advances and this forms an important parameter for staging of chronic pancreatitis (CP) in various classification systems.

Research frontiers
------------------

Various pancreatic function tests are available to assess the exocrine pancreatic function (EPF). This study focussed on comparing faecal elastase-1 (FE-1) estimation and the results of acid steatocrit test for evaluating EPF for use in the staging of pancreatitis by the M-ANNHEIM system.

Innovations and breakthroughs
-----------------------------

The results of this study show that stool fat analysis by acid steatocrit and FE-1 correlate well with each other. The estimation of FE-1 detected EPI, in a significantly higher number, thereby placing a larger number of patients in higher stages of disease as per the M-ANNHEIM classification.

Applications
------------

This study shows that FE-1 is a more appropriate pancreatic function test to determine EPI and to stage pancreatitis using the M-ANNHEIM classification.

Terminology
-----------

FE-1 measures the amount of pancreatic elastase enzyme secreted into the gut by the pancreas and is estimated by the enzyme-linked immunosorbent assay technique. FE-1 is a tubeless indirect pancreatic function test which relies on the stability of pancreatic elastase as it transits through the intestine before excretion in stool. FE-1 is highly sensitive in estimating EPI during advanced stages of CP. Steatorrhoea by the acid steatocrit method is determined by diluting the stool with distilled water and homogenising it followed by mixing the stool with Perchloric acid to a pH of less than 1. The stool mixture is transferred to a capillary tube, and centrifuged to obtain a fat layer and a solid layer, which is measured by the appropriate formula to measure the stool fat content in the given stool sample.
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